Oparina N Iu, Sadritdinova A F, Snezhkina A V, Dmitriev A A, Krasnov G S, Senchenko V N, Mel'nikova N V, Belenikin M S, Lakunina V A, Veselovskiĭ V A, Stepanov O A, Kudriavtseva A V
Genetika. 2012 May;48(5):599-607.
Multiple changes in the genome, transcriptome, and proteome are frequent in cancer cells. A search for molecular markers based on DNA, mRNA, or proteins is a main method to develop early specific diagnostics for cancer. While universal markers are still unavailable, similar trends are known for the expression patterns of particular genes in certain epithelial tumors. A bioinformatic screening of transcriptomic databases identified the NETO2 gene as a new potential promising marker of renal cancer. A substantial increase in NETO2 mRNA level was detected in 90% clear-cell renal cell carcinomas, 70% of non-small cell lung cancers, and 50% of papillary renal cancers by real-time PCR. The NETO2 mRNA level was increased to a lesser extent in cervical carcinoma and colon cancer and tended to decrease in cancer of the stomach. The NETO2 gene, which codes for a membrane glycoprotein with an unclear function, was assumed to provide a new promising marker for early diagnosis in renal cancer and non-small cell lung cancer.
基因组、转录组和蛋白质组的多种变化在癌细胞中很常见。基于DNA、mRNA或蛋白质寻找分子标志物是开发癌症早期特异性诊断方法的主要手段。虽然通用标志物仍然无法获得，但某些上皮性肿瘤中特定基因的表达模式存在相似趋势。对转录组数据库进行生物信息学筛选后，确定NETO2基因为肾癌一个新的潜在的有前景的标志物。通过实时PCR检测发现，90%的透明细胞肾细胞癌、70%的非小细胞肺癌和50%的乳头状肾癌中NETO2 mRNA水平大幅升高。NETO2 mRNA水平在宫颈癌和结肠癌中升高程度较小，在胃癌中则有下降趋势。NETO2基因编码一种功能不明的膜糖蛋白，被认为可为肾癌和非小细胞肺癌的早期诊断提供一个有前景的新标志物。
